Human Papillomavirus: Knowledge in students of General Secondary in Pachuca, Hidalgo
DOI:
https://doi.org/10.19230/jonnpr.3762Keywords:
Human Papillomavirus, Knowledge, Vaccine, Prevention, Cervical CancerAbstract
Introduction. The human papilloma virus (HPV) is the main etiologic factor of cervical cancer (CaCu) which constitutes a global public health problem, especially in developing countries. More than 120 types of HPV virus have been described, however, types 16 and 18 are responsible for 70% of cervical cancer cases. The importance of Knowledge about prevention and transmission is essential to avoid infection or achieve early detection.
Objective. To determine the level of knowledge about HPV prevention of the students at the General Secondary School No. 1 in Pachuca, Hidalgo.
Materials and methods. Cross-sectional, observational study, the information was obtained from a questionnaire applied to the students at a General Secondary School in the state of Hidalgo. Descriptive analyses were performed, measures of central tendency and dispersion were calculated for continuous variables and ratios and proportions were obtained for qualitative variables.
Results. 96.5% of the respondents reported having heard about HPV, more tan 90% believe that this disease is curable. Regarding vaccination, 50% expressed knowing the age at which the vaccine should be applied. Only 76% reported having the first doce of the vaccine, however, only 17% applied all the necessary doses ofi t.
Conlusions. To improve the health leve lof the mexican population, it is necessary to implement a preventive action program guarantteing coverage in HPV vaccination. If this type of program is not implemented, the results will not be entirely positive.
Downloads
References
Zaldívar Lelo de Larrea G, Martín Molina F, Sosa Ferreyra C, Ávila Morales J, Lloret Rivas M, Román Lara M et al. Cáncer cervicouterino y virus del papiloma humano. Revista chilena de obstetricia y ginecología. 2012;77(4):315- 321.
Concha MR. Diagnosis and treatment of human papilloma virus. Rev. Chil. Infect. 2007;24(3): 209-14.
Martínez-Martínez L, Cuesta Cambra U. Conocimiento y actitudes hacia el virus del papiloma humano en una población de universitarios españoles = Knowledge and attitudes towards human papillomavirus in a population of Spanish university students. REVISTA ESPAÑOLA DE COMUNICACIÓN EN SALUD. 2018;9(1):14.
Sanabria Negrín JG. Human Papilloma virus (HPV). Rev. Ciencias Médicas. 2009;13(4).
OMS. Guide to Introducing HPV Vaccine into National Immunization Programmes. 1st ed. Ginebra: OMS; 2017.
Aragón-Franco FR, López-Macías CR, Estrada-García IC, Astudillo-de la Vega H. El papel de los Toll Like Receptors (TLRs) en la respuesta inmune innata contra el cáncer cérvico-uterino. Rev. Sanid. Milit. Mex. 2010;64(6):287-99.
Bustamante Ramos G, Martínez-Sánchez A, Tenahua-Quitl I, Jiménez C, López Mendoza Y. Conocimiento y prácticas de prevención sobre el virus del papiloma humano (VPH) en universitarios de la Sierra Sur, Oaxaca. Anales de la Facultad de Medicina. 2016;76(4):369.
Rivera R, Aguilera J, Larraín A. Epidemiología del Virus del Papiloma Humano (VPH). REV. CHIL. OBSTET. GINECOL. 2002;67(6): 501-6.
Chavez Rivera K. Nivel de conocimiento y conductas de riesgo para contraer el virus del papiloma humano en dos instituciones educativas de San Juan de Miraflores, noviembre 2016 [Licenciatura]. Universidad Nacional Mayor de San Marcos; 2017.
Hernández-Hernández DM, Apresa-García T, Patlán-Pérez RM. Panorama epidemiológico del cáncer cervicouterino. Rev Med Inst Mex Seguro Soc. 2015;53 Supl 2: S154-61. PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26462510
Bosch FX, Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers. 2007; 23(4):213-27.
Diario Oficial de la Federación (DOF). NORMA Oficial Mexicana NOM-036-SSA2-2012, Prevención y control de enfermedades. Aplicación de vacunas, toxoides, faboterápicos (sueros) e inmunoglobulinas en el humano. Available from: http://dof.gob.mx/nota_detalle.php?codigo=5270654&fecha=28/09/2012 [Accessed 5 may 2020].
Organización Mundial de la Salud (OMS). Papilomavirus humanos (PVH) y cáncer cervicouterino. Available from: https://www.who.int/es/news-room/factsheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer [Accessed 5 may 2020].
Luna Blanco M, Sánchez Ramírez G. Posibilidades sociales de prevención de la infección por virus del papiloma humano y de cáncer cervicouterino en San Cristóbal de Las Casas, Chiapas, México. LiminaR Estudios Sociales y Humanísticos. 2014;12(2):67.
European Commission. Virus del Papiloma Humano (VPH). Available from: https://ec.europa.eu/health/vaccination/hpv_es [Accessed 5 May 2020].
Gamboa O, Murillo R. Estimación de la carga económica de las lesiones preneoplásicas y el cáncer de cuello uterino en Colombia. Implicaciones para la vacunación contra el VPH. Revista Colombiana de Cancerología. 2016;20(2):61-72.
Chavaro Vicuña N, Arroyo Hernández G, Felipe Alcázar L, Muruchi Garrón GW, Pérez Zúñiga I. Cáncer Cervicouterino. An. Radiol. Méx. 2009;1:61-79.
Ochoa Carrillo F. Mitos y realidades de la vacunación contra el virus del papiloma humano. Gaceta Mexicana de Oncología. 2015;14(4):214-221.
Vacunas contra el VPH [Internet]. National Cancer Institute. 2019 [cited 27 May 2019]. Disponible en: https://www.cancer.gov/espanol/cancer/causasprevencion/riesgo/germenes-infecciosos/hoja-informativa- vacuna-vph [Internet]. Paho.org. 2019 [cited 27 May 2019]. Disponible en: https://www.paho.org/hq/dmdocuments/2016/3-Vacuna-VPH.pdf
Dirección General de Epidemiología (DGE). Anuario de morbilidad 1984-2018. Available from: http://www.epidemiologia.salud.gob.mx/anuario/html/anuarios.html [Accessed 5 may 2020].
Torres Poveda K, Madrid-Marina V. Understanding the development of cervical cancer - Joint efforts to improve HPV and cervical cancer diagnosis. Impact. 2018;2018(3):58-59.
Instituto Nacional del Cáncer. Vacunas contra el virus del papiloma humano (VPH). Available from: https://www.cancer.gov/espanol/cancer/causasprevencion/riesgo/germenes-infecciosos/hoja-informativa- vacuna-vph [Accessed 5 may 2020].
Virus del papiloma humano (VPH) - Salud pública - European Commission [Internet]. Salud pública European Commission. 2019 [cited 27 May 2019]. Disponible en: https://ec.europa.eu/health/vaccination/hpv_es
Kably Ambe A, Ruiz Moreno JA, Lazcano Ponce E, Vargas Hernández VM, Aguado Pérez RA, Ruiz PA. Consenso para la prevención del cáncer cervicouterino en México. Ginecol. Obstet. Mex. 2011;79(12):785-787.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
